Stanley-Laman Group
GSK icon

Stanley-Laman Group’s GSK GSK Stock Holding History

Stanley-Laman Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.93M Sell
102,446
-2,678
-3% -$137K 0.54% 51
2026
Q2 		$5.51M Sell
105,124
-52
-0% -$2.75K 0.56% 46
2026
Q1 		$5.8M Buy
105,176
+1,040
+1% +$56.4K 0.71% 40
2025
Q4 		$5.11M Buy
104,136
+7,073
+7% +$330K 0.65% 41
2025
Q3 		$4.19M Sell
97,063
-781
-0.8% -$30.5K 0.6% 54
2025
Q2 		$3.76M Sell
97,844
-25,688
-21% -$982K 0.56% 80
2025
Q1 		$4.79M Buy
123,532
+16,313
+15% +$597K 0.74% 41
2024
Q4 		$3.63M Sell
107,219
-23,241
-18% -$837K 0.51% 84
2024
Q3 		$5.33M Buy
130,460
+23,293
+22% +$953K 0.75% 31
2024
Q2 		$4.13M Buy
107,167
+97,578
+1,018% +$4.1M 0.59% 68
2024
Q1 		$411K Hold
9,589
– – 0.06% 198
2023
Q4 		$355K Buy
+9,589
New +$344K 0.05% 199
2017
Q2 		– Sell
-45,129
Closed -$2.38M – 210
2017
Q1 		$2.38M Sell
45,129
-9,116
-17% -$462K 0.64% 51
2016
Q4 		$2.61M Buy
54,245
+30,211
+126% +$1.49M 0.81% 29
2016
Q3 		$1.3M Sell
24,034
-1,278
-5% -$70.1K 0.53% 45
2016
Q2 		$1.37M Sell
25,312
-3,930
-13% -$207K 0.54% 45
2016
Q1 		$1.48M Sell
29,242
-43,300
-60% -$2.16M 0.28% 88
2015
Q4 		$3.66M Sell
72,542
-657
-0.9% -$33.5K 0.63% 47
2015
Q3 		$3.52M Sell
73,199
-2,141
-3% -$111K 0.72% 41
2015
Q2 		$3.92M Buy
75,340
+77
+0.1% +$4.34K 0.72% 44
2015
Q1 		$4.34M Buy
75,263
+5,281
+8% +$303K 0.79% 44
2014
Q4 		$3.74M Buy
69,982
+2,364
+3% +$132K 0.71% 46
2014
Q3 		$3.88M Buy
67,618
+473
+0.7% +$29K 0.75% 40
2014
Q2 		$4.49M Buy
67,145
+40
+0.1% +$2.71K 0.82% 40
2014
Q1 		$4.48M Buy
67,105
+9,284
+16% +$628K 0.78% 42
2013
Q4 		$3.86M Buy
+57,821
New +$3.75M 0.84% 40

Other funds holding GSK

Mondrian Investment Partners
Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
ABC Arbitrage
ABC Arbitrage Paris, France $1.02B AUM 30.46% 1-Year Est. Return
Foster Victor Wealth Advisors
Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return
Sound Income Strategies
Sound Income Strategies Ft Lauderdale, Florida $2.24B AUM 8.38% 1-Year Est. Return
Euro Pacific Asset Management
Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return
Keystone Financial Planning
Keystone Financial Planning Cleveland, Ohio $404M AUM 16.77% 1-Year Est. Return
Bell Bank
Bell Bank Fargo, North Dakota $2.66B AUM 18.07% 1-Year Est. Return

Stanley-Laman Group's GSK Position: Q3 2026 in Review

Stanley-Laman Group reduced its GSK (GSK) stake by 2.5% in Q3 2026, selling an estimated $137K and leaving 102,446 shares worth $4.93M. The position accounts for 0.54% of the portfolio, ranked #51.

Stanley-Laman Group first reported a position in GSK in Q4 2013 and has held it in 26 quarters since. The position peaked at $5.8M in Q1 2026. 266 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

  • Stanley-Laman Group held 102,446 shares of GSK worth $4.93M as of Q3 2026.
  • Stanley-Laman Group sold 2,678 GSK shares in Q3 2026, an estimated $137K.
  • GSK made up 0.54% of Stanley-Laman Group's portfolio in Q3 2026, its #51 holding.
  • Stanley-Laman Group first reported a position in GSK in Q4 2013 and has held it in 26 quarters since.
  • Stanley-Laman Group's GSK position peaked at $5.8M in Q1 2026.
  • 266 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Stanley-Laman Group's 13F filing for Q3 2026, filed 20 Oct 2026.